Limited space available for pre-APP workshops

Pharmacists are being encouraged to enrol in additional training before APP to bring themselves up-to-date and learn hands-on methods to help them practice to their full potential.

“I invite my colleagues to join a workshop on Wednesday, 19 May, one day before APP. They are being conveniently held at the Gold Coast Convention and Exhibition Centre,” says APP Convenor Kos Sclavos AM.

APP’s Official Education Partner, the Australasian College of Pharmacy, is also running a not-to-be-missed workshop on Wednesday, 19 May.

The Australasian College of Pharmacy CEO, Dr Dimitri Kopanakis, says that the pre-APP seminar would provide attendees with updates on vital clinical topics, including practical approaches to treating patients with chronic health conditions, triptans for migraines, adapalene, cannabidiol, melatonin, Covid-19 vaccinations, and holistic vaccination approaches.

“The seminar contains a workshop that is underpinned by a complex chronic care case study to explore the prescribing competencies necessary to address harm minimisation, therapy adaptation and deprescribing,” says Dr Kopanakis.

“The seminar contains seven hours of content. The ACP is currently seeking CPD accreditation,” says Dr Kopanakis, “The workshop supports pharmacists to practice to their full potential and brings together leading academic, community and hospital pharmacist speakers.”

“I’m pleased to announce the expert line-up of speakers, including Dr Treasure McGuire, Dr David Pache, Nicolette Ellis and Dr Brett MacFarlane, Chief Pharmacist for the Australasian College of Pharmacy,” says Dr  Kopanakis.

The Pharmacy Guild of Australia and Australasian College of Pharmacy members can take advantage of special rates offered for both APP and the pre-conference workshops. Attendees can book their APP2021 registration and pre-conference workshop at: appconference.com.

Must Read

New hope to treat women with early breast cancer

0
For the first time in 15-years women with an invasive form of early breast cancer that has a high risk of returning after initial...